Citizens analyst Reni Benjamin reiterated a Market Perform rating on Sutro Biopharma (NASDAQ: STRO).The anayst commented, "Last week, Sutro announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE